ID: ALA199856

Max Phase: Preclinical

Molecular Formula: C25H27N5O4

Molecular Weight: 461.52

Molecule Type: Small molecule

Representations

Canonical SMILES:  CCCn1c(=O)c2nc(-c3ccc(OCC(=O)c4ccc(C)cc4)cn3)[nH]c2n(CCC)c1=O

Standard InChI:  InChI=1S/C25H27N5O4/c1-4-12-29-23-21(24(32)30(13-5-2)25(29)33)27-22(28-23)19-11-10-18(14-26-19)34-15-20(31)17-8-6-16(3)7-9-17/h6-11,14H,4-5,12-13,15H2,1-3H3,(H,27,28)

Standard InChI Key:  FLISLAXKLUZUMM-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 461.52

Molecular Weight (Monoisotopic): 461.2063

AlogP: 3.34

#Rotatable Bonds: 9

Polar Surface Area: 111.87

Molecular Species: NEUTRAL

HBA: 8

HBD: 1

#RO5 Violations: 0

HBA (Lipinski): 9

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 6.76

CX Basic pKa: 0.58

CX LogP: 3.73

CX LogD: 3.19

Aromatic Rings: 4

Heavy Atoms: 34

QED Weighted: 0.38

Np Likeness Score: -1.19

References

1. Carotti A, Cadavid MI, Centeno NB, Esteve C, Loza MI, Martinez A, Nieto R, Raviña E, Sanz F, Segarra V, Sotelo E, Stefanachi A, Vidal B..  (2006)  Design, synthesis, and structure-activity relationships of 1-,3-,8-, and 9-substituted-9-deazaxanthines at the human A2B adenosine receptor.,  49  (1): [PMID:16392813] [10.1021/jm0506221]

Source

Source(1):

• Scientific Literature